Abstract 2325P
Background
In KRAS-mutant NSCLC cells, SHOC2:MRAS:PP1C complex boosted RAS GTP loading and MAPK pathway reactivation after initial MEK suppression. Nuclear export protein exportin 1 (XPO1) is dependent on KRAS-mutant NSCLC cells, making XPO1 a druggable vulnerability. MET and SHOC2 are required for spheroid growth in KRAS-mutant NSCLC cell lines. Using structure-based drug design (SBDD), we looked at whether selinexor and tepotinib could bind into the 1) KRAS G12C His-95 groove like sotorasib (KRAS G12C inhibitor); 2) SHOC2 phosphatase complex in comparison with celestrol (SHOC2 inhibitor).
Methods
We carried out an in silico molecular docking approach with KRAS G12C and the SHOC2 complex against selinexor and tepotinib using SBDD to determine the binding affinity, intermolecular interactions, and ligand structure complementarity. Sotorasib-resistant H358 and parental H358 KRAS G12C NSCLC cells were examined. In vitro growth inhibitory assays determined cell viability after 3-day treatment. Western blot analyses were performed.
Results
The molecular docking results are summarized in the table. Selinexor and tepotinib interacted with all the three proteins of the complex, unlike celestrol interacting with SHOC2 and MRAS. Within the His-95 groove of KRAS G12C, selinexor forms an H bond and tepotinib forms a pi-sulphur and an H bond with the mutant cys12 residue. Selinexor in combination with tepotinib and omeprazole (v-ATPase inhibitor) has been analyzed. Signaling pathway analysis to demonstrate the SHOC2 and KRAS G12C inhibition is ongoing.
Conclusions
In silico modeling predicts that selinexor and tepotinib have more interactions and better binding affinity with the target proteins when compared to the standard inhibitors. In vitro data will be presented on the validation of selinexor and tepotinib for repositioning in KRAS G12C NSCLC. Table: 2325P
Target proteins | Ligands | Binding affinity (Kcal/mol) | Number of hydrogen (H) bonds | Other interactions |
SHOC2 complex | Tepotinib | -10.3 | 2 | 3 |
Selinexor | -9.6 | 5 | 6 | |
Celestrol | -8.8 | 3 | 0 | |
KRASG12C | Tepotinib | -9.1 | 2 | 1 |
Selinexor | -9.4 | 6 | 6 | |
Sotorasib | -8.2 | 3 | 2 |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2222P - Frequent TERT gains in metastatic papillary thyroid carcinoma
Presenter: Sara Gil
Session: Poster session 16
2223P - Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer
Presenter: Sergi Clavé
Session: Poster session 16
2224P - Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry
Presenter: Maria Victoria San Roman Gil
Session: Poster session 16
2225P - FOX1 (rs965513), NKX2-1 (rs944289) and BRAF (V600E) gene mutations and their role in development of papillary thyroid cancer
Presenter: Darko Katalinic
Session: Poster session 16
2226P - Survival benefit of radioiodine therapy (RAI) in papillary thyroid cancer variants (PTCV): A SEER analysis
Presenter: Sakhr Alshwayyat
Session: Poster session 16
2227P - The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: A single-arm phase II clinical trial
Presenter: Jianhong Yu
Session: Poster session 16
2228P - Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution
Presenter: Ryutaro Onaga
Session: Poster session 16
2229P - Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
Presenter: Lori Wirth
Session: Poster session 16
2323P - Multi-omic spatial phenotyping of the NSCLC tumour microenvironment for the development of a spatial score associated with immunotherapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 16
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Presenter: Ander Puyalto
Session: Poster session 16